CT-guided Radioactive 125I Seed Implantation for Abdominal Incision Metastases of Colorectal Cancer: Safety and Efficacy in 17 Patients |
| |
| Affiliation: | 1. Mary Lanning Healthcare, Morrison Cancer Center, Hastings, NE;2. University of Nebraska Medical Center, Omaha, NE;3. Mary Lanning Healthcare Pathology, Hastings, NE;4. Mary Lanning Healthcare Radiology, Hastings, NE;5. Prairie Center Internal Medicine & Nephrology, Green Island, NE;1. Department of Gastrointestinal Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX;2. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX;3. Department of Colorectal Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX;4. Department of Gastrointestinal Medical Oncology;1. Department of Radiation Oncology, City of Hope National Medical Center, Duarte, CA;2. Department of Medical Oncology, City of Hope National Medical Center, Duarte, CA;3. Department of Surgery, City of Hope National Medical Center, Duarte, CA;1. Third Department of Medical Oncology, “Agii Anargiri”General Hospital and Cancer Center, Athens, Greece;2. Department of Medical Oncology, University Hospital of Ioannina, Ioannina, Greece;3. Second Department of Medical Oncology, “Agii Anargiri” General Hospital and Cancer Center, Athens, Greece;4. Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, Athens, Greece;1. Division of Colon and Rectal Surgery, Department of Surgery, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Korea;2. Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Korea |
| |
| Abstract: | IntroductionTo retrospectively evaluate the safety and efficacy of computed tomography (CT)-guided iodine-125 (125I) seed implantation for patients with abdominal incision metastases from colorectal cancer.Materials and MethodsData of patients with abdominal incision metastases of colorectal cancer from November 2010 to October 2020 were retrospectively reviewed. Each incisional metastasis was percutaneously treated with 125I seed implantation under CT guidance. Follow-up contrast-enhanced CT was reviewed, and the outcomes were evaluated in terms of objective response rate, complications, and overall survival.ResultsA total of 17 patients were enrolled in this study. The median follow-up was 18 months (range, 2.7-22.1 months). At 3, 6, 12, and 18 months after the treatment, objective response rate was 52.9%, 63.6%, 33.3%, and 0%, respectively. A small amount of local hematoma occurred in two patients and resolved spontaneously without any treatment. Two patients experienced a minor displacement of radioactive seeds with no related symptoms. Severe complications, such as massive bleeding and radiation injury, were not observed. No ≥ grade 3 adverse events were identified. By the end of follow-up, 14 patients died of multiple hematogenous metastases. The one-year overall survival rate was 41.6%, and the median overall survival was 8.6 months.ConclusionCT-guided 125I seed implantation brachytherapy is safe and feasible for patients with abdominal incision metastases from colorectal cancer. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
